Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review
Primary Central Nervous System Lymphoma (PCNSL) is a rare variant of Non-Hodgkin Lymphoma (NHL) representing 1-2% of all NHL cases. PCNSL is defined as a lymphoma that occurs in the brain, spinal cord, leptomeninges, or eyes. Efforts to treat PCNSL by traditional chemotherapy and radiotherapy have generally been unsuccessful as a significant proportion of patients have frequent relapses or are refractory to treatment. The prognosis of patients with Refractory or Relapsed (R/R) PCNSL is abysmal. The optimal treatment for R/R PCNSL is poorly defined as there are only a limited number of studies in this setting. Several studies have recently shown that ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, has promising results in the treatment of R/R PCNSL. However, these are preliminary studies with a limited sample size. In this systematic review, we explored and critically appraised the evidence about the efficacy of the novel agent ibrutinib in treating R/R PCNSL.
Nepal, G., Khurana, M., Bucheli, D. H., Bhandari, S., Joshi, U., Bhagat, R., Rehrig, J. H., Pudasainee, P., Shing, Y. K., Ortiz, J. F., Ojha, R., Gajurel, B. P., Quinonez, J., Ruxmohan, S., Albert, T., Licata, S., & Stien, J. (2022). Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review. Neurology International, 14 (1), 99-108. https://doi.org/10.3390/neurolint14010009